These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12820312)

  • 1. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
    Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
    Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening.
    Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
    Anticancer Res; 2003; 23(2A):855-7. PubMed ID: 12820313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer.
    Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD
    Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data].
    Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD
    Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faecal tumour pyruvate kinase M2: not a good marker for the detection of colorectal adenomas.
    Shastri YM; Stein JM
    Br J Cancer; 2008 Oct; 99(8):1366; author reply 1367. PubMed ID: 18827821
    [No Abstract]   [Full Text] [Related]  

  • 6. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer.
    Hardt PD; Ngoumou BK; Rupp J; Schnell-Kretschmer H; Kloer HU
    Anticancer Res; 2000; 20(6D):4965-8. PubMed ID: 11326648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy.
    Hardt PD; Ewald N
    Expert Rev Mol Diagn; 2008 Sep; 8(5):579-85. PubMed ID: 18785806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of different stool tests for the detection of cancer of the colon].
    Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G
    Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
    Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Performance of a Fecal Tumor M2-PK Rapid Kit Using Stool Specimens for Detection of Colorectal Tumors.
    Cho CH; Kim J; Jang MA; Lee BJ; Park JJ; Lim CS
    Ann Clin Lab Sci; 2016; 46(2):154-60. PubMed ID: 27098621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK.
    Schneider J; Bitterlich N; Schulze G
    Anticancer Res; 2005; 25(3A):1507-15. PubMed ID: 16033052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer.
    Schulze G
    Anticancer Res; 2000; 20(6D):4961-4. PubMed ID: 11326647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
    Kumar Y; Tapuria N; Kirmani N; Davidson BR
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing of multiple samples increases the sensitivity of stool decay-accelerating factor test for the detection of colorectal cancer.
    Mizuno M; Mizuno M; Iwagaki N; Nasu J; Okazaki H; Yamamoto K; Okada H; Tsuji T; Fujita T; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2550-5. PubMed ID: 14638362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal Adnab-9 binding as a risk marker for colorectal neoplasia.
    Yuan M; Xhang X; Leu Y; Xu Y; Ullah N; Lawson M; Tobi M
    Cancer Lett; 2006 Apr; 235(1):48-52. PubMed ID: 15893419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
    Schneider J; Schulze G
    Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal lysozyme: an unreliable marker for colorectal cancer.
    Dubrow R; Kim CS; Eldred AK
    Am J Gastroenterol; 1992 May; 87(5):617-21. PubMed ID: 1595650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical significance of blood and fecal tumor M2-pyruvate kinase expression in patients with colorectal cancer].
    Li Y; Wang JJ
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):2087-9. PubMed ID: 22200720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor type M2 pyruvate kinase expression in advanced breast cancer.
    Lüftner D; Mesterharm J; Akrivakis C; Geppert R; Petrides PE; Wernecke KD; Possinger K
    Anticancer Res; 2000; 20(6D):5077-82. PubMed ID: 11326672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stool test for colorectal cancer screening--it's time to move!
    Loitsch SM; Shastri Y; Stein J
    Clin Lab; 2008; 54(11-12):473-84. PubMed ID: 19216253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.